Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Official Title

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Summary:

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.

Trial Description

Primary Outcome:

  • Duration of progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 by blinded independent central review (BICR) (Arms A and B only)
  • Duration of Overall survival (OS) (Arms and B only)
Secondary Outcome:
  • Duration of PFS per RECIST v1.1 by investigator assessment (Arms A and B only)
  • Overall response rate (ORR) per RECIST v1.1 by BICR (Arms A and B only)
  • ORR per RECIST v1.1 by investigator assessment (Arms A and B only)
  • Duration of response (DOR) per RECIST v1.1 by BICR (Arms A and B only)
  • DOR per RECIST v1.1 by investigator assessment (Arms A and B only)
  • Disease control rate (DCR) per RECIST v1.1 by BICR (Arms A and B only)
  • DCR per RECIST v1.1 by investigator assessment (Arms A and B only)
  • Change from baseline in patient reported outcome assessment measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L)
  • Change from baseline in patient reported outcome assessment measured by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)
  • Change from baseline in patient reported outcome assessment measured by Brief Pain Inventory - Short Form (BPI-SF)
  • Incidence of adverse events (AEs)
  • Incidence of laboratory abnormalities
  • Treatment discontinuation rate due to AEs
This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care gemcitabine + platinum-containing chemotherapy, in subjects with previously untreated locally advanced or metastatic urothelial cancer. Enfortumab vedotin may be administered for an unlimited number of cycles until a protocol defined reason for study discontinuation occurs. Pembrolizumab may be administered for a maximum of 35 cycles or a protocol-defined reason for study discontinuation occurs, whichever is first. Cisplatin or carboplatin plus gemcitabine may be administered for a maximum of 6 cycles or a protocol-defined reason for study discontinuation occurs, whichever is first.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society